Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
2,328 people get THLD articles and Market Currents by email alert.
Get email alerts on THLD »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Marketwire (May 2, 2013)
-
-
-
-
-
-
-
Marketwire (Mar 21, 2013)
-
-
Threshold Pharmaceuticals Reports Fourth Quarter and Year End 2012 Financial and Operational ResultsMarketwire (Mar 7, 2013)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Today's Market News To Trade On: 5 Stocks Moving On NewsMatthew Smith • Tue, Sep 18, 2012 -
-
-
There are no Transcripts on THLD.
-
Marketwire (May 2, 2013)
-
Marketwire (Mar 21, 2013)
-
Threshold Pharmaceuticals Reports Fourth Quarter and Year End 2012 Financial and Operational ResultsMarketwire (Mar 7, 2013)
-
Marketwire (Nov 2, 2012)
-
Marketwire (Oct 4, 2012)
-
Marketwire (Sep 18, 2012)
-
at CNBC.com (Sep 17, 2012)
-
at MarketWatch.com (Sep 17, 2012)
THLD vs. ETF Alternatives
Company Description
Currently, there's no company description for THLD.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, May 2, 10:52 AM Threshold Pharmaceuticals (THLD): Q1 EPS of -$0.16 misses by $0.07. Revenue of $2.9M beats by $0.1M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Tuesday, March 26, 11:23 AM Threshold Pharmaceuticals (THLD +1.3%) gains on the back of Ziopharm's (ZIOP -63%) earlier announcement that it's ending Phase 3 trials of palifosfamide after it failed to meet its primary endpoint. An article posted in Seeking Alpha last Friday infers that THLD's competing drug, TH-302, although similar to palifosfamide in molecular structure, is differentiated enough in nature that there is still sufficient reason to believe it could work. Now, with ZIOP's drug out of the running, TH-302's addressable market increases significantly. The company is due to release data from its own Phase III study early next year. 1 Comment [Healthcare, On the Move]
-
Tuesday, March 26, 9:15 AM
Premarket gainers: THLD +8%. CTIC +6%.
Losers: ZIOP -62%. PLCE -6%. PATH -6%. Comment! [On the Move] - Thursday, March 7, 7:34 AM Threshold Pharmaceuticals (THLD): Q4 EPS of -$0.10 misses by $0.01. Revenue of $2.02M misses by $0.8M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Wednesday, February 20, 9:56 AM Threshold Pharmaceuticals (THLD +7.2% to $4.78) receives an upgrade to Overweight from Neutral from Piper Jaffray, which is impressed with the differentiation of Threshold's TH-302 drug for soft-tissue sarcoma compared with a rival product. Piper also believes that Threshold's hypoxia-activation platform will be able to be used to treat a wide range of cancers. Piper doubled the company's price target to $10. Comment! [Healthcare, On the Move, Quick Ideas]
-
Wednesday, February 20, 9:10 AM
Premarket gainers: NTSP +30%. NVGN +14%. JASO +9%. SINA +8%. GDOT +8%. THLD +8%. RMBS +8%. OMX +7%. ODP +7%. MDRX +6%. GALE +5%.
Losers: HNR -41%. MM -27%. ONCY -12%. GRMN -9%. LIFE -5%. Comment! [On the Move] - Friday, January 25, 9:26 AM Threshold Pharmaceuticals (THLD) +6.3% premarket after earning a $30M milestone payment from drug partner Merck (MRK), which started a late-stage study of THLD's pancreatic cancer drug. TH-302 is an investigational hypoxia-targeted drug designed to be activated under severe tumor hypoxic conditions, a hallmark of many cancers. 1 Comment [Healthcare, On the Move]
-
Friday, January 25, 9:10 AM
Premarket gainers: INFA +10%. TPX +10%. ECTE +9%. OSK +8%. STP +6%. THLD +7%. SNE +6%.
Losers: SCSS -15%. BGMD -15%. EGHT -10%. SFL -8%.
1 Comment [On the Move] - Wednesday, January 23, 2:43 PM Threshold Pharmaceuticals (THLD +18%) soars after Celgene (CELG -0.7%) reported positive Phase III data for Abraxane, its prospective treatment for pancreatic cancer, but the data came in slightly below analysts' expectations. Stifel Nicolaus reiterated a Buy on THLD after the news, saying that its own treatment will be more competitive with CELG's product. Comment! [Healthcare, On the Move]
-
Wednesday, January 23, 12:45 PM
Midday top 10 gainers: MAPP +59%. HMNF +34%. JAXB +26%. CREE +19%. DQ +18%. THLD +16%. KERX +15%. SMCI +15%. SILC +14%. FSGI +14%.
Midday top 10 Losers: STRI -25%. COH -15%. NMRX -15%. STSI -14%. URRE -12%. FU -12%. IAG -11%. GVP -10%. TTM -10%. VLTR -10%. Comment! [On the Move] - Friday, January 18, 9:17 AM Geron (GERN) +5.4% after an upgrade to Buy with $3 price target by Piper Jaffray's Charles Duncan. The current price of $1.66 reflects past challenges, he says, but leaves room for substantial upside over the course of the next year. That Geron and INO are buys at Piper while ZIOT and THLD are Holds does not compute, says Dan Rosenblum. Sell-side games, says TheStreet's Adam Feuerstein. 1 Comment [Healthcare, On the Move]
-
Thursday, January 10, 12:45 PM
Midday top 10 gainers: UCBA +48%. NOK +19%. VOXX +17%. NEWL +16%. FSCI +16%. MY +15%. HAST +15%. HGG +13%. SVU +12%. PTIE +11%.
Midday top 10 Losers: MCP -21%. GIG -21%. DRWI -20%. UNXL -14%. PRXI -8%. QRM -8%. ASNA -8%. THLD -8%. SSRI -8%. PRGN -7%. 1 Comment [On the Move] - Thursday, November 15, 2012, 8:49 AM Updated results from a Phase II trial of Threshold's (THLD) TH-302 treatment suggest that the drug can be used in patients with soft-tissue sarcoma, first in combination with chemotherapy doxorubicin, and then on its own as a maintenance treatment. The results support Phase III trials of the regimen. Threshold shares +10.3%. (PR) Comment! [Healthcare, On the Move, M&A]
- Friday, November 2, 2012, 7:45 AM Threshold Pharmaceuticals (THLD): Q3 EPS of -$0.06 in-line. Revenue of $1.8M misses by $0.5M. (PR) Comment! [Earnings, Healthcare]
- Tuesday, October 16, 2012, 2:00 PM Threshold Pharmaceuticals (THLD), returns to earth following a big burst higher at the open. The stock jumped on the drug developers announcement that U.S. regulators have reached an agreement covering a special protocol assessment for Phase III trials of it's TH-302 drug candidate, a treatment for patients with metastatic pancreatic cancer. Comment! [Healthcare]
-
Tuesday, October 16, 2012, 9:10 AM
Premarket gainers: NOOF +54%. THLD +12%. MUR +8%. AEGR +7%. JOEZ +7%. CUR +7%. DPZ +6%.
Losers: RATE -26%. ISIS -20%. CLWR -19%. CMRE -10%. WAC -5%. GWW -5%. 1 Comment [On the Move]
-
- View all 0 replies
-
Red Acre Investments
Sent out Red Acre's weekly review last night $ZIOP, $RPRX, $AMRN, $VVUS, $APPA, $UTHR, $THLD signup at http://www.redacre.com to get it. - View all 3 replies
-
Red Acre Investments: Thx for the kind words - Happy Easter to you as well.
-
-
TruffelPig
Fute stars in biotech: http://bit.ly/W9bQXv $ECYT $THLD $INO of mine are there. (INO as of tomorrow) - View all 1 replies
-
-
- View all 12 replies
-
drpharm: its legitimate, i have to wait until tomorrow, buts its okay, im on the upside overall because of your picks. its just a flesh wound haha -
-
Michael Bryant
So glad I told someone to not buy Threshold Pharmaceuticals (THLD). http://yhoo.it/Udlw3U - View all 1 replies
-
-
- View all 0 replies
-
- View all 0 replies
-
- View all 9 replies
-
-
-
- View all 1 replies
-
TruffelPig: Shame on Benzinga for this one. The drug is obviously not Doxo.......
-
- View all 20 replies
-
Maria Auziliadora: previously evidently you do not know nothing about the market
-
LATEST REPLIES
-
Red Acre Investments
Sent out Red Acre's weekly review last night $ZIOP, $RPRX, $AMRN, $VVUS, $APPA, $UTHR, $THLD signup at http://www.redacre.com to get it. - View all 3 replies
-
Red Acre Investments: Thx for the kind words - Happy Easter to you as well.
-
-
TruffelPig
Fute stars in biotech: http://bit.ly/W9bQXv $ECYT $THLD $INO of mine are there. (INO as of tomorrow) - View all 1 replies
-
-
Scott Matusow
Have fun with my new pick = $THLD Will include it on article for tomorrow, then a feature. ASCO trade with huge potential - View all 12 replies
-
-
Sinjjn Smythe: sold at around $8 last time. havent bought any in while. i will keep my eye it to see when it will take off again. :-)
-
- View all 12 replies
-
drpharm: its legitimate, i have to wait until tomorrow, buts its okay, im on the upside overall because of your picks. its just a flesh wound haha
-
-
Michael Bryant
So glad I told someone to not buy Threshold Pharmaceuticals (THLD). http://yhoo.it/Udlw3U - View all 1 replies
-
-
- View all 9 replies
-
-
-
- View all 1 replies
-
TruffelPig: Shame on Benzinga for this one. The drug is obviously not Doxo.......
-
- View all 20 replies
-
Maria Auziliadora: previously evidently you do not know nothing about the market
-
-
- View all 8 replies
-
-
-
The Scientist
THLD Response to blog by S Church. Median age diff between tx groups not statis signif. Lung mets TH302>gem group-lung mets worse than liver - View all 3 replies
-
The Scientist: Th302 is a breakthru drug! If Church can think of another way to kill hypoxic CSCs, let us know. This drug gives panc pts hope!
-
The Scientist: Panc ca is one of the most diff diseases (not just ca) to tx. Everything but the kitchen sink has been tried. Th302 will revolutionize ca tx
-
The Scientist
Solid OS data for THLD Th-302 in panc ca. OS+2.5 mos in highest dose. Tarceva approved with 0.4 mos. Discontinuation rate lowest for highest - View all 2 replies
-
The Scientist: TH-302 dose. High prob FDA approval. Huge unmet need. Gemzar initial approval based on 126 pts (Gemzar insert). Adcetris approv 102/58 pts
-
The Scientist: Huge improvement PFS/OS over current SOC. Good safety profile-fewer discontinuations with highest dose.
-
The Scientist
THLD with continued high short interest. Of all the stocks to short, this is one of the worst. Solid data. Potential to go up 10x quickly - View all 3 replies
-
The Scientist: Th-302 could be the breakthru drug that oncologists have been looking for. By targeting hypoxic niche, kills CSCs that promotes recurrence
-
The Scientist: Hypoxic CSCs r the 'untouchables' in oncology. Must b killed, but cannot get to them.
-
- View all 1 replies
-
-
The Scientist
THLD Th-302 OS panc CA data likely to b > Abraxane OS. Abrax trial began 3/09. Near end of trial on 9/11, protocol changed and added 210 pts - View all 3 replies
-
-
Noreika: OT- That was a bummer yesterday that Bapi got cancelled. I really thought the Apo4 non-carriers would have some positive news.
-
The Scientist
By targeting the hypoxic niche, THLD Th-302 can kill CSCs, where CSCs are known to reside. Killing CSCs are key to cancer tx. - View all 1 replies
-
